Small cap company Remedium Lifecare share price zoomed 1.90% to Rs 2.14 apiece as Sensex surged 1436.75 points to 74,574.65 in late afternoon trade on April 8. The stock also hit 2nd consecutive upper circuit as well after the company announced Rs 49.19 crore rights issue for expansion. Meanwhile, the company has a market capitalisation of Rs 86.28 crore. Remedium Lifecare shares witnessed impressive rally of 12.04% in last 1-week as Sensex plunged 1.90% during the similar timespan. In last 1-year, the stock slid 92.89%. Check more details below:
Remedium Lifecare Announces Rights Issue
According to the BSE filing of Remedium Lifecare dated April 8, 2025, “It has received approval from the Bombay Stock Exchange (BSE) for its proposed rights issue. The approval paves the way for the company to raise growth capital from its existing shareholders, further strengthening its financial foundation and supporting its strategic initiatives, including manufacturing expansion, product development, and global market penetration.”
“This approval from the BSE marks a significant milestone in our journey. We remain committed to enhancing shareholder value while scaling up our operations responsibly and sustainably,” said Adarsh Munjal , Whole Time Director, Remedium Lifecare Ltd.
The record date for rights issue is April 15, 2025. The issue size is Rs 4,919.04 Lakhs with price per share at Re 1.00 per equity share. The total number of shares stood at 49,19,04,000 fully paid-up equity shares of face value Re 1/- each, added the exchange filing.
Earlier this year on February 15, 2025, Remedium Lifecare Limited bagged a multi-year supply contract from renowned pharmaceutical distribution company based in the United Kingdom. This contract encompassed the supply of a range of Active Pharmaceutical Ingredients (APIs), Intermediates, and Specialty Chemicals. The estimated value of the supplies scheduled from February 2025 to January 2026 alone is approximately One Hundred Eighty Two Crores Seventy Lakh Rupees only (Rs.182,70,00,000/-).
Remedium Lifecare Shares Performance
The 52-week high price of Remedium Lifecare share on BSE is Rs 30.50 per share (as on 08/04/2024) and 52-week low price is Rs1.73 per share (as on 01/04/2025), respectively. Remedium Lifecare shares gained over 1% in last 2-weeks, slipped over 63% in last 3-months, and fell 71.8% in last 2-years. In last 3-years, Remedium Lifecare stock price surged over 73.9% and offered impressive gain of 970.00% in last 5-years.
Remedium Lifecare Q3 Results
It announced sharp dip in its net profit for the quarter ended December 2024 at Rs 0.76 crore, down 98.34% year-on-year (YoY) as against Rs 45.82 crore reported in the corresponding quarter of last year. It reported its revenue from operations for Q3FY25 at Rs 38.15 crore from Rs 1834.17 crore declared in the similar quarter of last year. Total income for December 2024 quarter announced at Rs 45.58 crore as against Rs 1848.29 crore in the same quarter of last year. The EPS of Remedium also recorded steep fall to Rs 0.02 for the quarter ended December 2024 from Rs 22.73 declared in the corresponding quarter of last year.
Remedium Lifecare Bonus Share In 2024
Remedium Lifecare announced bonus share in the proportion of 3:1 in 2024 and set July 5, 2024 as the record date. It has recommended bonus shares twice so far since 2023.
Remedium Lifecare Stock Split In 2024
It split the face value of its share twice since 2023. Remedium Lifecare last split the face value of its shares from Rs 5 to Re 1 in 2024.The share traded ex-split as on February 23, 2024, according to Trendlyne.
Remedium Dividend
The company never recommended any dividend since Jan 1, 2000.
Disclaimer: The story highlights rights issue and should not be considered as investment advice by the Moneydaily.in or the Author. Moneydaily.in and the author will not be held responsible for any losses caused as a result of decisions based on the above information. Moneydaily.in advises readers to do their own research or consult a SEBI registered investment advisor before making any investment decisions.
Recommended: Muthoot Finance To Consider Results, Dividend; Shares Outperform Market
Leave a Reply